Pharma BD Deal Intelligence
High-conviction hedge: BMS commits $1.5B upfront plus $2B in non-contingent payments through 2028 for BioNTech's BNT327, splitting costs and profits 50/50 on a bispecific still unproven on overall survival.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bristol Myers allies with BioNTech on bispecific cancer drug BNT327, with total deal value up to $11.1 billion including $7.6 billion in development,…
BMS buys into BioNTech bispecific antibody, putting up $1.5 billion to collaborate in multiple cancers. Leerink Partners' Daina Graybosch called out the…
Bristol Myers Squibb paid BioNTech $3.5 billion to co-develop the asset, reflecting pumitamig's potential to replace Keytruda as the backbone of…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
BMS and BioNTech entered a global co-development and co-commercialization partnership for the PD-L1 x VEGF-A bispecific antibody BNT327 (INN: pumitamig; BMS-986545) across multiple solid tumors. Under the agreement (signed June 2, 2025; amended and restated August 15, 2025), BMS pays $1.5B upfront plus $2B in non-contingent anniversary payments through 2028, with up to $7.6B in development/regulatory/commercial milestones (total up to $11.1B), and the parties share global development costs and profits 50/50. The collaboration became effective in Q3 2025 — BioNTech received the $1.5B upfront and recognized BMS collaboration revenue in its Q3 2025 results. Pumitamig is in a broad late-stage program including pivotal Phase 3 ROSETTA Lung-01 (1L extensive-stage SCLC) and Phase 2/3 ROSETTA Lung-02 (1L NSCLC), with ROSETTA Breast-01 (1L TNBC), ROSETTA CRC-203 and ROSETTA GI-204 planned/initiated.
255K US cases/yr · $50.0B Global PD-1/PD-L1 checkpoint inhibitor market 2024 (Keytruda alone $29.5B in 2024) · 1000 Patients treated globally across BNT327 trials to date
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) represent the two primary commercialization targets for BNT327 (pumitamig). Lung and bronchus cancer is estimated at 226,650 new US cases in 2025 (SEER), with NSCLC accounting for approximately 85% (~190,000 cases) and SCLC approximately 13% (~30,000 cases). SCLC has historically been characterized by aggressive progression, limited second-line options, and poor survival — extensive-stage disease has a 5-year survival rate below 10%. First-line standard-of-care for extensive-stage SCLC is chemotherapy plus PD-L1 inhibitor (atezolizumab or durvalumab). Triple-negative breast cancer (TNBC) represents approximately 10-15% of the ~310,000 annual US breast cancer cases (~35,000-45,000 patients) and remains a high unmet-need subset lacking hormone receptor and HER2 targets. NSCLC first-line metastatic standard-of-care is anchored by pembrolizumab (Keytruda) +/- chemotherapy, with emerging competition from PD-L1/VEGF bispecifics representing a potential next-generation IO backbone. BNT327 is being evaluated in global Phase 3 trials in 1L extensive-stage SCLC and 1L NSCLC, with Phase 2 data in TNBC.
BNT327 competes in the emerging PD-(L)1/VEGF bispecific antibody field that aims to displace or complement anti-PD-1/PD-L1 monotherapy in 1L solid tumors. Direct PD-L1/VEGF bispecific competitor: ivonescimab (SMT112, Summit Therapeutics/Akeso) — PD-1/VEGF bispecific that has shown mixed Phase 3 NSCLC data with survival signal controversy; leading ex-China asset in class. PD-1 monotherapy incumbents: Keytruda (pembrolizumab, Merck) — market leader, 2024 sales $29.5B; Opdivo (nivolumab, BMS) — established IO backbone; Tevimbra (tislelizumab, BeiGene) — US-approved 2024. PD-L1 inhibitors: Tecentriq (atezolizumab, Roche), Imfinzi (durvalumab, AstraZeneca). Emerging IL-2/PD-1 bispecifics: IBI363 (Innovent/Takeda). Anti-VEGF monotherapy/combo: Avastin (bevacizumab, generic). BNT327's differentiation thesis rests on combining checkpoint blockade with anti-angiogenic activity in a single molecule; BMS adds pipeline combinations including ADC, anti-CCR8, and anti-CTLA-4 (Yervoy/ipilimumab).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / BioNTech SE (this deal) | 2025 | $11.1B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2025 deals · Bristol-Myers Squibb Company deals · Oncology deals